Home > Boards > Canadian > Medical - Healthcare >

Champignon Brands Inc. (SHRMF)

SHRMF RSS Feed
Add SHRMF Price Alert      Hide Sticky   Hide Intro
Moderator: JohnCM, MustBeTheTruth
Search This Board: 
Last Post: 5/31/2020 1:59:30 AM - Followers: 35 - Board type: Free - Posts Today: 1

      
Champignon Brands Inc.
 
Champignon Brand Inc. is a research driven Company specializing in Mushroom Health Supplements that promote Holistic Health and Wellness.
---------------------------------------------------------------------------------------------------------------------------
The Canadian based company dedicated to the distribution of artisial, medical mushrooms and associated CPGs.
------------------------------------------------------------------------------------------------------------------------------
The Champignon team believes that we enhance the health and wellness of Millions of consumers through the distribution of their premium, mushrrom-infused suite of products.
-----------------------------------------------------------------------------------------------------------------------------
Champignon Brands Inc is a member of The AMerican Mushroom Institue (AMI). The Institue is a national voluntary trade association representing the growers, processors and marketers of the cultivated mushroom in the United States and the industry worldwide. Membership is available to any person interested in the mushrrom industry.
Categories of membership are grower, associate, professional and retiree.

Whats are AMI's Purpose?
-Anticipate and respond to issues affecting mushrrom production, processing and marketing.
-Monitor and influence legislative and regulatory issues.
-Support, analyze and disseminate relevant information such as research, statistics, and innovations in technology.
-Develop best practices and training in food safety, integrated pest management and worker safety
-Provide a communications network for all industry partners.
For more than 60 years, the AMerican Mushroom Institue has been a leader for the United STates mushrrom industry. When an industry speakers with one voice through a trade association, the results are for greater than what could be achieved by any single individual.
---------------------------------------------------------------------------------------------------------------------------

Vitality Superteas 
"Maximize your well-being One delicious cup at a Time"

Vitality Superteas is on a mission to help people acheive their health gaols and to provide the best product and serice possible to make sure you can enhance your life and reach new level of balance and well being.

Champignon's mushrrom-derived CPG portfolio included the flagship brand
Vitality Superteas' SKU's are formulated with the goal of revolutionizing conventional organic tea through the infusion of a proprietary blend of artensial mushrooms with medicinal properties.

https://vitalitysuperteas.com/
------------------------------------------------------------------------------------------------------------------------------
Artisan Growers Ltd.
Artisan Growers operates a craft mushroom cultivation facility capable of producing an assortment of
organic craft mushroom varietals including Lion’s Mane, Chaga, Reishi and Agaricus Blazei.

------------------------------------------------------------------------------------------------------------------------------
DRIP

Cofee / Social
Champignon Brands has a consignment agreement with Drip Coffee Social LTD.
Champignon Brands and Drip Coffee Social Ltd. have also entered into R&D and Product Formulation partnership whereby Drip will infuse Champignon's Propretary mushrrom extract blend into a suite of cold brew coddee products and signature in-house formulations.
------------------------------------------------------------------------------------------------------------------------------

Novo Formulation Ltd.
Champignon said it's going to be using Novo's technologies for the delivery of MDMA (3,4-Methyl?enedioxy?methamphetamine) and psilocybin.
-------------------------------------------------------------------------------------------------------------------------------
Tassili Life Sciences Corp. 
Expanding the Company’s preclinical trial pipeline, as well as its
aggregation of broad intellectual property (IP) related to the development of novel psychedelics
therapeutics and their delivery systems, targeting multiple pathological psychological diseases.
Tassili, in partnership with a multidisciplinary team of scientists and physicians at the University of
Miami are working to develop effective psilocybin-based therapeutics for the treatment of mild
traumatic brain injuries (mTBI) and/or post-traumatic stress disorder (PTSD).
-------------------------------------------------------------------------------------------------------------------------------

CEO, Corporate Secretary & Director : Dr. Roger McIntyre
CFO
,....................................................: Mr. Steven Broham
Director,..............................................: Mr. Jerry Habuda
Director
,...............................................: Mr. Joseph Perino
DIrector,................................................:Mr. Matthew Fish
Special Advisory Committee
..............:Dr. Joseph Gabriele
Tassili , U of M ......................................Dr. Michael Hoffer
Special Advisory Committe
................:Mr. Jay Kheita, ACPR,

This Decriminalization Drive Could Be Bigger Than The Cannabis Boom

MENAFN - Wed May 6, 2:57PM CDT

FN Media Group Presents Financialmorningpost.com Market Commentar

New York, NY - May 6, 2020 - Millions across the globe are struggling with their mental health, and the COVID-19 pandemic is compounding a crisis that has been ignored throughout history. The U.S. alone spent $89 billion just on mental illness treatment in a single year in 2013, and the roof on those spending figures has disappeared. Mentioned in today's commentary includes: Aurora Cannabis Inc. (NYSE:ACB) (TSX:ACB.TO), Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON.TO), Constellation Brands, Inc. (NYSE:STZ), Canopy Growth Corporation (NYSE:CGC) (TSX:WEED.TO), Molson Coors Beverage Company (NYSE:TAP).

When the post-COVID-19 veil is lifted, mental healthcare spending will skyrocket further and the world will emerge in a mental health haze that demands an elixir. The market for this healthcare segment is again ripe for major innovation.

The innovation will likely come from psychedelics-such as psilocybin, the active compound in 'magic mushrooms'-described by the Wall Street Journal as our return to nature that can help alleviate depression, anxiety and addiction.

And one disrupter will potentially be a little known company called Champignon Brands Inc ( SHRM ; SHRMF ) the innovative startup that aiming to position itself one step ahead of the world's mental health crisis.

With researchers closing in on the third decade of the "second wave" of psilocybin research, a consensus on the strong clinical potential of psilocybin is building among experts in psychiatry and psychopharmacology.

The psychedelics innovation is likely going to be massive, and Champignon Brands is looking to follow the examples of some of the biggest and most successful companies on the planet to dominate this brand new industry.

#1 The Decriminalization Drive

The Journal of Abnormal Psychology has blamed the increased use of smartphones and other digital media for increasing incidences of depression and suicide among adolescents and young adults; a view that is supported by the National Survey of Drug Use and Health (NSDUH).

According to the World Health Organization (WHO), 25% of the world's population will be afflicted by mental health and/or neurological disorders at some point throughout their lives 

With growing resistance to current antidepressant medications, more and more people are shunning conventional treatments, which they have to take for the rest of their lives, for radical new therapies of the future such as psilocybin.

In 2018, researchers at John Hopkins University released a study analyzing the Psilocybin's abuse potential, concluding that it should be rescheduled to Schedule IV , where most prescription benzodiazepines can be found.

Already, a growing number of jurisdictions have started to actively decriminalize Psilocybin and Psilocybin mushrooms. With Psilocybin decriminalization gathering momentum, it may not be long before the compound enters the mainstream mental health and wellness market.

Champignon Brands Inc. ( SHRM ; SHRMF ) is already positioned for that.

#2 Early Mover Advantage

Companies like Champignon Brands Inc. are looking to secure advantage in the medical Psilocybin space. And it's already got a leg up on the competition.

It owns an ecosystem from research and cultivation to formulations of cutting-edge premium products. But what's particularly impressive about this $35M company (market cap) is the Total Addressable Market (TAM) that it has in its cross-hairs.

Psilocybin (Magic Mushrooms) has been shown in research to be effective in the treatment of a wide array of mental health conditions including Drug Addiction, Alcoholism, Depression,Migraines, PTSD and Smoking Cessation.

The global functional mushroom market Champignon is looking to penetrate is expected to reach $34.3 billion by 2024, registering a CAGR of 8.04% during the forecasted period (2019 - 2024). But most importantly, it will have the massive $4.5 trillion Global Wellness Industry at its feet. These are incredible growth runways that Champignon Brands Inc. try to readily exploit for years and decades to come.

The psilocybin trend could potentially mimic the cannabis boom. When marijuana was decriminalized, a wave of cannabis companies soared as a result.

Take Aurora Cannabis (ACB), for example. Aurora Cannabis is one of the biggest names in the burgeoning marijuana sector. With a market cap nearly one billion dollars, Aurora has carved out its position as a leader in the industry.

In an announcement from Aurora, the company stated that the deal 'firmly establishes Aurora's first-mover advantage in one of the world's most populous countries, where more than 130 million people will have federally legal access to a range of Aurora's non-flower medical cannabis products containing THC.'

Cronos Group (CRON) was another first-mover in the space. The Canadian firm, though primarily an equity investor, has made some major moves in recent years, wheeling and dealing with some of the hottest names in the sector. Because of its forward-thinking attitude, it has drawn the attention of many major mainstream players, including the company behind Marlboro, Altria Group.

On December 7th, rumors were finally confirmed when Cronos made the official announcement of a C$2.4 billion strategic investment from Altria. "Altria is the ideal partner for Cronos Group, providing the resources and expertise we need to meaningfully accelerate our strategic growth," said Cronos Group's Mike Gorenstein, Chairman, President and Chief Executive Officer.

Canopy Growth Corporation (CGC) too saw its stock soar following the decriminalization wave. After securing a major $4 billion investment from beverage giant Constellation Brands, it seemed like Canopy Growth was on the top of the world.

Though things have cooled down a bit since then after a downgrade from analysts of the Constellation Brands stock, Canopy has not stopped making moves in the market, most recently swallowing up renowned vaporizer producer Stor & Bickel Gmbh & Co., the creator of the iconic Volcano(R) Medic and the Mighty(R) Medic devices

Even giant beverage brands joined the race. Constellation Brands (STZ) , a beverage conglomerate with a stake in everything from Corona to Modelo, shook up the pot world in August 2018 when it sank $4 billion into Canopy Growth Corp , buying itself a 38% stake.

Despite the recent departure of Canopy's CEO Bruce Linton, the deal still looks like a good one for Constellation, which has big plans for rolling out CBD and THC-infused beverages. And the upset at Canopy barely dents an otherwise stellar period for Constellation, which saw its stock price jump 11% in the second half of 2019.

Molson Coors (TAP) is another iconic multi-national beer company, with brands that are recognizable across the United States and Canada. Not to be left behind in the marijuana boom, Molson Coors is also developing a line of non-alcoholic cannabis-based beverages with its partner, the Hydropothecary Corporation.

Molson Coors Canada president and CEO Frederic Landtmeters noted , 'While we remain a beer business at our core, we are excited to create a separate new venture with a trusted partner that will be a market leader in offering Canadian consumers new experiences with quality, reliable and consistent non-alcoholic, cannabis-infused beverages.'

#3 100% Intellectual Property Ownership

Patents are the lifeblood of the biotech industry. Biotechnology is one of the most research-intensive industries, with companies in the sector typically investing between 40% and 50% of their revenues in research and development, compared to 13% in pharmaceuticals and 5% in the chemical industry. In many cases, IP rights can actually be the final product.

That's why Champignon Brands' ( SHRM ; SHRMF ) already impressive cache of pharmaceutical patents gives it a leg up in the competitive rush to claim market share in the nascent Psilocybin industry.

Normally, when you do clinical trials, the ideal is to own the resulting IP. Champignon is partnering with the University of Miami and Miller School of Medicine in its research work but will own 100% of the intellectual property, drug discovery, and resultant data.

Its Psilocybin Patent Portfolio will greatly help the company in the commercialization of GMO and vegan certified rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders. Even better: It can license its patented formulations to other companies as it deems fit.

#4 Smart Acquisitions

Acquisitions can make or break a company. With so much on the line, a smart takeover can send a company's stock into the stratosphere, while a questionable buyout could absolutely destroy investors' confidence in the company.

A big reason why Champignon Brands Inc.'s ( SHRM ; SHRMF ) is looking to hit the ground running is due to its impressive array of smart acquisitions.

Tassili , a 100% owned subsidiary, is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin in treating mTBI with PTSD or stand-alone PTSD; final results are expected in 2021.

Artisan Growers is another subsidiary 100% owned by Champignon Brands Inc.'s. Artisan Growers utilizes a variety of cultivation techniques and grow infrastructure to produce premium craft mushrooms. 

Champignon also wholly owns Novoformulations. Novoformulations is presently working with ketamine, anaesthetics and adaptogenics, as well as a host of pharmaceuticals and natural molecules at a purpose-built good manufacturing practice (GMP) and pharmaceutical (DIN) licensed facility, located in Quebec, Canada, and an accredited pharmacy in Ontario.

At a current valuation of just $65M, straddling incredible growth runways and an idea whose time has finally come, this is a company to watch.

By. Meredith Taylor

https://champignonbrands.com/




 
SHRMF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SHRMF News: As Health-Conscious Consumers Seek Fresh Nutritional Avenues, Artisanal Mushrooms Step into the Light 04/02/2020 08:45:00 AM
PostSubject
#218  Sticky Note Champignon Appoints Dr. Roger McIntyre as Chief Executive Officer JohnCM 05/12/20 02:06:06 PM
#369   CGC "only" lost a billion dollars in 4Q. Scumbag Fraudsters 05/30/20 04:35:31 AM
#368   Paid promotion to begin soon. Scumbag Fraudsters 05/30/20 04:14:18 AM
#367   Looks like this is the clear leader in Moonboy1 05/29/20 04:59:45 PM
#366   $RLTR SELLING IS COMPLETE! Let’s go up! Dallon 05/29/20 01:40:00 PM
#365   a new report out on SHRMF... in the namah sivaya 05/29/20 06:24:32 AM
#364   Thank you! I have my own board. JohnCM JohnCM 05/28/20 07:26:01 PM
#363   You are a visionary :) your timing happyglass 05/28/20 05:28:00 PM
#361   I am glad it filled that gap in happyglass 05/28/20 12:33:26 PM
#360   The correct question should be, Scumbag Fraudsters 05/24/20 06:29:28 PM
#359   Shrm starting 2.85 on Monday. I would love Andygotpho 05/23/20 12:07:38 PM
#358   I bought as much as I could today. JohnCM 05/22/20 02:11:01 PM
#357   Thank you!!!! Good idea. I wanted to initiate position JohnCM 05/22/20 12:12:49 PM
#355   In one month 0.45 to 1.82 Was looking for JohnCM 05/22/20 10:18:11 AM
#353   What's causing the crash?. Are people bolting for Moonboy1 05/22/20 10:13:36 AM
#352   And ... I was wrong. LOD 1.15 Now back JohnCM 05/22/20 09:38:11 AM
#351   RUN FOR THE HILLS! Scumbag Fraudsters 05/22/20 09:31:08 AM
#346   https://investorplace.com/2020/05/3-penny-stocks-to-buy-for-psychedelic-profits/ Mozley44 05/22/20 04:54:23 AM
#345   Had nice run up but really what’s up BreezeWoodAcres 05/21/20 09:25:39 PM
#344   You are probably right about flipping. I am JohnCM 05/21/20 07:45:16 PM
#343   According to the source of the tweet, he greenwillow 05/21/20 07:01:19 PM
#342   I am going to not watch. Not good JohnCM 05/21/20 06:45:03 PM
#341   Do you know if the company asked Chuck JohnCM 05/21/20 06:42:57 PM
#340   You didn't watch the video? greenwillow 05/21/20 06:07:54 PM
#339   I did not watch, on purpose. JohnCM 05/21/20 06:03:33 PM
#338   I am going out on a limb. It JohnCM 05/21/20 06:02:57 PM
#337   These valuation levels are way overblown, imo The greenwillow 05/21/20 05:46:38 PM
#336   Because it's on Twitter? Scumbag Fraudsters 05/21/20 05:11:43 PM
#335   It's official... greenwillow 05/21/20 02:54:52 PM
#334   Bounced off $1.25 again. Keep doing that and JohnCM 05/21/20 12:09:15 PM
#333   Lol. You think it would keep going straight Pwilly79 05/21/20 11:59:55 AM
#332   What going on people why shrm keep on dropping Andygotpho 05/21/20 11:08:53 AM
#331   Whoa LOD $1.33 Yesterday it was $1.25 Now $1.42 Good buy JohnCM 05/21/20 10:09:59 AM
#330   I was tempted, but I will hold just JohnCM 05/21/20 08:52:50 AM
#328   I probably played Champ right. Sold 1/2 near JohnCM 05/21/20 08:48:07 AM
#327   Well, we held $1.25 How long before we break $1.73?? JohnCM 05/21/20 08:46:07 AM
#326   chill till ATHs... maybe microdose? :) namah sivaya 05/21/20 08:44:47 AM
#325   No what for the chart?? JohnCM 05/21/20 08:11:13 AM
#324   Good test. Again held up OK. JohnCM 05/21/20 02:22:20 AM
#323   Stock just a little too ambitious. Dough rising BreezeWoodAcres 05/20/20 09:58:00 PM
#322   I'm watching all of them John starkd748 05/20/20 05:37:00 PM
#321   NEW SHROOM JohnCM 05/20/20 02:43:26 PM
#320   The deal is what brought me back. We raregar1 05/20/20 02:07:54 PM
#319   Psychedelic Penny Stocks To Watch Amid The Mushroom Boom JohnCM 05/20/20 12:48:23 PM
#318   Hahaha ok buddy. It’s what they do with Pwilly79 05/20/20 12:07:14 PM
#317   $NUMI Ipo today too Lipkin9393 05/20/20 12:06:12 PM
#316   LOW $1.25 JohnCM 05/20/20 11:38:49 AM
#315   IF YOU ARE GOING TO BUY OR ADD ... JohnCM 05/20/20 11:23:15 AM
#314   $1.25 WILL IT HOLD?? JohnCM 05/20/20 11:22:30 AM
#313   That is exactly what happened. Get the williamtrout 05/20/20 11:21:55 AM
#312   I agree!!! Some apples fall down and now Andygotpho 05/20/20 11:20:13 AM
PostSubject